home Health, Sports nutrition & Exercises, Weight Loss & Diet Tips Pioneering Clinical Treatment of Mixed Hematopoietic Chimerism to Induce Transplantation Tolerance

Pioneering Clinical Treatment of Mixed Hematopoietic Chimerism to Induce Transplantation Tolerance

“The Stanford Experience: Pioneering the Clinical Treatment of Mixed Hematopoietic Chimerism to Induce Transplantation Tolerance”

Speakers:
Everett Meyer, M.D., Ph.D., M.S.
Stephan Busque, M.D., MSc

About the Speakers:
Dr. Everett Meyer, M.D., Ph.D., M.S., is an Associate Professor in the division of Blood and Marrow Transplantation and Cellular Therapy, with courtesy appointments in Surgery and Pediatrics. He has a focus on the pre-clinical and clinical study of immune tolerance. He serves as director of the Cellular Immune Tolerance program supported by DOM and Surgery, which receives critical clinical trial support from SCCR. His scientific focus is the study of hematopoietic chimerism and T regulatory cell therapy.

Dr. Stephan Busque, M.D., is a Professor in the division of Abdominal Transplantation Surgery. He serves as Director of the Adult Kidney and Pancreas Transplant Program and Surgical Director of the Cellular Immune Tolerance Program and is widely regarded as a leading expert in the clinical implementation of immune tolerance in kidney transplantation. His research interest is focused on the improvement of clinical immunosuppression. He is involved in the evaluation of new immunosuppressive drugs, potentially more efficacious or less toxic, with the ultimate goal to achieve tolerance.